Shots:
- BioVersys & Shionogi have entered into a global research & exclusive license option agreement to co-develop novel ansamycin compounds from BioVersys’ BV500 program into clinical candidates for treating NTM infections
- Shionogi will gain access to BioVersys’ ansamycin chemistry platform & BV500 program, with an exclusive option to license selected molecules for clinical development & global commercialization
- As per the terms, BioVersys will receive CHF 5M (~$6.3M) in upfront & near-term research payments & will be eligible to receive up to CHF 479M (~$605.2M) in regulatory & sales milestones, with tiered royalties on global sales, if Shionogi exercises its license option after clinical candidate selection
Ref: Globenewswire | Image: BioVersys & Shionogi | Press Release
Related News:- Takeda Reports US FDA Approval of GAMMAGARD LIQUID ERC for Primary Immunodeficiency
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
